Replication protein A (RPA) is a trimeric singlestranded DNA (ssDNA)-binding complex of eukaryotic cells that plays an important role in DNA metabolism by stabilising single-stranded regions of DNA. The functionally important binding activity towards ssDNA is mainly localised on the large subunit, RPA70, whereas the middle subunit, RPA32, appears to have a regulatory function. It has been shown previously that RPA32 is phosphorylated both during the S-phase of a normal cell cycle and in response to DNA damage. In this study we demonstrate that phosphorylation of RPA32 is rapidly induced during apoptotic cell death of Jurkat T-lymphocytes, resulting in a hyperphosphorylated form with reduced electrophoretic mobility. In contrast, the large subunit of RPA is neither modified nor cleaved during apoptosis. Phosphorylation of RPA32 begins in parallel to the degradation of DNA to high molecular weight fragments, and slowly continues until late apoptosis. Experiments with specific kinase inhibitors indicate that RPA32 hyperphosphorylation requires the activities of DNA-dependent protein kinase and of a cyclin-dependent protein kinase. Interestingly, the hyperphosphorylated, but not the less phosphorylated forms of RPA32, sediments independently from the trimeric complex in sucrose gradients under high ionic strength, and is not bound to the complex in immunoprecipitation assays.
INTRODUCTION
Replication protein A (RPA) is a heterotrimeric protein complex originally purified from human cells as an essential component for SV40 DNA replication in vitro (1) (2) (3) . Homologous proteins have later been found in all eukaryotes including yeast (4) , and have been implicated not only in DNA replication, but also in DNA recombination and repair (for a current review see 5). In general, RPA seems to be involved in all aspects of DNA metabolism that require single-stranded DNA (ssDNA) intermediates. RPA is an abundant protein with 3 × 10 4 -2 × 10 5 molecules per nucleus of human cells (6, 7) and represents the major ssDNA binding protein in eukaryotic cells. Interestingly, RPA also binds to double-stranded DNA (dsDNA), although with an affinity that is several orders of magnitude lower than its affinity to ssDNA (4, 8) . RPA prefers certain sequences or secondary structural elements in dsDNA with the consequence that bound RPA is able to unwind dsDNA regions up to several thousand base pairs at low ionic strength in vitro (9) .
RPA is a stable complex composed of three subunits known as RPA70, RPA32 and RPA14 with reference to their approximate molecular masses. The major DNA binding activity of RPA is associated with the RPA70 subunit which contains a central region with two adjacent DNA binding domains and, most likely, a third and weak binding domain in the C-terminal region (10, 11 ). An additional weak DNA binding domain appears to reside on the RPA32 subunit which may, therefore, contribute to the overall DNA binding activity of RPA (12) . The function of the smallest subunit, RPA14, is less well known, but RPA14 appears to be involved in RPA complex assembly and stability (13) .
Importantly, RPA32 is phosphorylated in a cell-cycle-dependent manner and in response to DNA damage (14) (15) (16) (17) . This subunit was therefore considered to be a regulatory component of the complex. Phosphorylation of RPA32 occurs at multiple serine residues in the N-terminal 35 amino acids, and causes a retardation in SDS gel electrophoresis corresponding to a 2-4 kDa increase in apparent molecular weight (17) (18) (19) . In vitro, RPA32 can be phosphorylated by many different kinases, including the cyclindependent kinase-2 family (CDK2), DNA-dependent protein kinase (DNA-PK), and several ill-defined kinases (15, 18, (20) (21) (22) (23) . In vivo, phosphorylation of RPA32 appears to be catalysed primarily by DNA-PK (22, 24) , although the present study demonstrates that cyclin-dependent kinase (CDK) activity may also be involved.
Even though many details of the phosphorylation of RPA have been described, its physiological role remains unknown. Phosphorylation of RPA32 stimulates the DNA unwinding activity of RPA (25), but is not required for DNA replication or repair (21, 22, 26) . Extracts depleted of DNA-PK are unable to phosphorylate RPA32, but support DNA replication (22) . Indeed, phosphorylated and unphosphorylated RPA have equal activity in in vitro DNA replication assay (27) . In addition, mutant forms of RPA32 lacking the N-terminal phosphorylation sites are not phosphorylated, but nevertheless assemble normally into the trimeric complex and have no negative effect on DNA replication in vitro (19, 26) . These data suggest that phosphorylation of RPA32 is not essential for the function of the RPA complex in DNA replication. However, as phosphorylation of RPA32 is highly conserved in evolution, and occurs only in the presence of ssDNA, it has been proposed that phosphorylation of RPA32 might act as a cellular messenger signalling the presence of ssDNA in the nucleus (22) .
Given the data on RPA phosphorylation after DNA damage (14,16), we found it interesting to investigate whether RPA is phosphorylated during apoptosis, which is accompanied by a massive degradation of genomic DNA. In the present study, we show that RPA32 is hyperphosphorylated during apoptotic cell death involving activities of DNA-PK and CDKs. We also show that the hyperphosphorylated RPA32 detaches from the trimeric complex.
MATERIALS AND METHODS

Cell culture and apoptosis induction
Jurkat cells were grown in RPMI1640 medium containing 10% fetal calf serum at 37_C in a humidified atmosphere, and passaged every 3 days by 5-fold dilution into fresh medium. All experiments reported in this paper were performed with cells 4 days after passaging, when >95% of cells were in G 1 , to reduce the background of S-phase specific RPA phosphorylation evident in exponentially growing cells. For induction of apoptosis, Jurkat cells were pelleted for 5 min at 190 g and washed twice in serum-free medium before addition of anti-CD95 antibody (CH-11, Immunotech, final concentration 100 ng/ml). For assays with kinase or caspase-3 inhibitors, cells were preincubated with the inhibitor (1 mM of OK-1035, butyrolactone I or olomoucine, or 200µM DEVD-CHO) for 30 min before antibody addition, and cells were analysed 3 h after induction of apoptosis.
Preparation of total cell extracts
Total cell extract for gel analysis was prepared from 1 ml of cell culture. Cells were harvested by centrifugation, resuspended in 360 µl of water, and immediately lysed by addition of SDS to 1% (final concentration). The clear, viscous lysate was sonified for 30 s to shear the genomic DNA. Total protein was precipitated by methanol/chloroform extraction as described in (28) , and redissolved in SDS sample buffer (29) .
Native total cell extract used for immunoprecipitation or sucrose gradient analysis was prepared by harvesting cells by centrifugation, resuspension in lysis buffer (10 mM Tris pH 8.0, 50 mM NaCl, 0.4% Triton X-100, plus 10 mM NaF and 20 mM β-glycerophosphate as phosphatase inhibitors), and disruption by sonication. The turbid lysate was then layered over an equal volume of 30% sucrose in lysis buffer and centrifuged at 4000 g for 15 min. Experiments were performed using the clear supernatant.
In vivo labelling with 32 P-orthophosphate
Jurkat cells were washed twice in phosphate-free/serum-free DME medium and then incubated in the same medium with 0.5 mCi 32 P-orthophosphate. After 30 min of preincubation, cells were split into two aliquots. Apoptosis was induced by adding CH-11 antibody to one of the aliquots; the other aliquot served as non-apoptotic control. After 3 h, cells were harvested by centrifugation to prepare native cell extract as described above.
Immunoprecipitation
Immunoprecipitations were performed with native cell extracts prepared from apoptotic and non-apoptotic cells (250 µg total protein per assay), 5 µg of affinity purified polyclonal anti-RPA antibody (30) or 50 µl monoclonal anti-RPA70 (Dianova), and 25 µl Protein A-Sepharose, in a total volume of 500 µl for 1 h at 4_C. Immunoprecipitations were washed six times each with 1 ml of lysis buffer. Precipitated proteins were eluted by boiling in SDS-PAGE sample buffer and analysed by denaturing PAGE (29) and immunoblotting (31) with affinity purified antibodies (32), peroxidase coupled secondary antibody (Sigma) and enhanced chemiluminiscent detection (ECL, Amersham).
Sucrose gradient centrifugation
Native cell extract was layered over a gradient from 25 to 5% sucrose in lysis buffer. For the experiments of Figure 5 , extract and sucrose gradient were adjusted to 1 M NaCl before centrifugation to disrupt RPA/DNA interactions. Centrifugation was performed in a SW40 rotor (Beckman) for 60 h at 4_C and 35 000 r.p.m. The gradient was fractionated into 20 fractions of 600 µl each. Aliquots from each fraction were analysed by SDS gel electrophoresis and western blotting as described above.
RESULTS
Time course of RPA phosphorylation
To investigate whether RPA is affected in apoptosis, Jurkat human leukaemic T-cells were exposed to a monoclonal antibody against the cell surface receptor CD95 (Fas/Apo-1) (reviewed in 33). This system is well established in apoptosis research (33) and has recently been applied in this laboratory to demonstrate the caspase-3 catalysed cleavage of the human scaffold attachment factor A (SAF-A) (34) . In the present study, SAF-A was used as a positive control to monitor the progress of cells through apoptosis.
The fate of RPA during apoptosis was first investigated by PAGE of total cell extracts prepared at different time points after induction of apoptosis and immunoblotting with affinity-purified polyclonal antibodies against RPA. No detectable change in the electrophoretic mobility of the large subunit (RPA70) could be detected, whereas a significant amount of the middle subunit (RPA32) was converted into a form with higher apparent molecular mass (Fig. 1) . A shift of RPA32 was first detected at 45 min after induction of apoptosis and correlated with the degradation of genomic DNA to high molecular weight fragments ( Fig. 1A ) (34) , but occurred well before the cleavage of SAF-A. The pattern of shifted RPA32 bands changed during apoptosis from four equally spaced bands at early time points to one predominant band at late time points (Fig 1C, asterisk) . This distribution of RPA32 bands is reminiscent of phosphorylation of RPA32 either during S-phase or after DNA damage (14) (15) (16) (17) . Thus, the reduced mobility of RPA32 during apoptosis could be the result of phosphorylation. To support this conclusion, we prepared an extract from cells induced to undergo apoptosis in the presence of 32 P-orthophosphate. Immunoprecipitation of RPA from this extract showed indeed that labelled RPA32 with the mobility of the shifted bands could be immunoprecipitated with polyclonal antibodies to the total RPA complex ( Fig. 2A) . Furthermore, a treatment of native total cell extracts with alkaline phosphatase before electrophoretic separation and immunoblotting removed the shifted band and restored the original electrophoretic mobility of RPA32 (Fig. 2B) .
From these experiments, we conclude that RPA32 is rapidly phosphorylated during apoptosis, giving rise to a hyperphosphorylated form with reduced electrophoretic mobility. In contrast, RPA70 is neither cleaved nor phosphorylated in apoptotic Jurkat cells.
As pointed out in the introduction, one of our motivations to study the fate of RPA in apoptosis had been the finding that RPA is phosphorylated in response to DNA damage (14, 16) . The observed hyperphosphorylation of RPA32 could, therefore, be the consequence of massive DNA degradation in apoptosis. Interestingly, however, a specific peptide inhibitor to caspase-3 that blocks the late stages of apoptosis-including the degradation of DNA to oligonucleosomal fragments-has little effect on phos- phorylation (Fig. 3) . Thus, phosphorylation of RPA32 appears to be independent of caspase-3 activity and DNA 'laddering'.
Inhibition of RPA32 phosphorylation
In vitro, phosphorylation of RPA32 can be catalysed by several different kinases, the best characterised being CDKs and DNA-PK. To obtain information concerning the kinase responsible for the apoptotic RPA32 phosphorylation in vivo, we induced apoptosis in the presence of specific inhibitors for DNA-PK or CDKs alone or in combination. To inhibit DNA-PK, we used OK-1035 [3-cyano-5-(4-pyridyl)-6-hydrazonomethyl-2-pyridone], a substance previously shown to inhibit phosphorylation of DNA-PK model substrates in vitro and p53 in vivo (35, 36) . As inhibitors for CDK activity, we used butyrolactone I (37,38) and olomoucine (39) . At 1 mM final concentration, both of these Figure 3 . Phosphorylation of RPA32 is not a consequence of massive DNA degradation ('laddering'). Cells were induced to undergo apoptosis either in the absence or presence of DEVD-CHO, a specific inhibitor of caspase 3 that also blocks DNA laddering. Phosphorylation of RPA32, DNA laddering and caspase 3-catalysed cleavage of SAF-A were analysed 4 h after induction and in untreated control cells (lanes 'C') . Left, analysis of DNA degradation in an agarose gel. Note that DNA laddering is completely inhibited in apoptotic cells in the presence of DEVD-CHO. Middle, SDS-PAGE of total cell extracts. Right, immunoblotting of the same extracts with polyclonal antibodies against SAF-A and RPA. The positions of SAF-A, its apoptotic cleavage product SAF-A*, and of the large and middle subunit of RPA (RPA70, RPA32) are indicated. Note that RPA32 is phosphorylated both in the absence and presence of DEVD-CHO. substances inhibit CDK1, 2 and 5, but not CDK4 and CDK6 in vivo (reviewed in 40).
In our studies, inhibitors to both types of kinase activity reduced the amount of hyperphosphorylated RPA32 (Fig. 4) . Interestingly, however, a combination of both inhibitors almost completely blocked RPA32 phosphorylation. This result is consistent with the possibility that both kinases, DNA-PK and CDKs, are involved in RPA32 phosphorylation. The inhibition of phosphorylation was not caused by a general block of apoptosis by either of these inhibitors, because SAF-A continued to be cleaved in the presence of the inhibitors. In addition, microscopic examination revealed that the cellular phenotypes of apoptotic Jurkat cells were very similar in the presence or absence of the CDK inhibitors butyrolactone I and olomoucine. The DNA-PK inhibitor OK-1035 did also not block apoptosis, but instead appeared to cause a more pronounced fragmentation of cells to apoptotic vesicles (data not shown). Thus, even though phosphorylation of RPA32 is a characteristic event in apoptotic cell death as outlined above, it appears to not be essential for apoptosis to occur, at least in the cell culture model we investigated.
Sucrose gradient analysis of apoptotic RPA complexes
To better understand the consequences of RPA phosphorylation, we performed sucrose gradient centrifugations of extracts from apoptotic cells and from control cells. Initial experiments under physiological salt concentration revealed a strong heterogeneity in the sedimentation coefficient of RPA from 5S to >18S in extracts from apoptotic cells (but not from control cells), most probably because much RPA associates with DNA fragments that arise during DNA degradation in apoptotic cells (data not shown). Therefore, sucrose gradient centrifugations were performed in the presence of 1 M NaCl to disrupt interactions between RPA and DNA. Salt treatment resulted in a uniform sedimentation of RPA ( Fig. 5) . Interestingly, the sedimentation rates of RPA increased from 5.0S in control cells to ∼6.0S in apoptotic cells, suggesting that a conformational change has occurred. Furthermore, the Figure 6 . Hyperphosphorylated RPA32 is not co-immunoprecipitated by RPA70 antibodies. Native cell extracts from control and apoptotic cells, 250 µg total protein per assay, were subjected to immunoprecipitation with a monoclonal antibody against RPA70. Both the supernatant and the precipitated material were resolved by SDS-PAGE, and RPA was visualised by polyclonal antibodies against the RPA complex. Note that the hyperphosphorylated form of RPA32 does not co-precipitate with RPA70, indicating it is not bound to the complex. Last lane, longer exposure of the penultimate lane to compensate for the low efficiency of immunoprecipitation. Asterisk, heavy chain of the antibody used for immunoprecipitation.
hyperphosphorylated form of RPA32 detached from the complex at moderately elevated ionic strength (>400 mM, data not shown) and sedimented in sucrose gradients as free protein with ∼3S (Fig. 5B, asterisk) . In contrast, unphosphorylated RPA32 or the less phosphorylated forms remained tightly associated with the trimeric RPA complex even at 1 M NaCl, in agreement with previous reports (1,3) . To confirm the dissociation of the hyperphosphorylated RPA32 subunit from the complex, we performed immunoprecipitations with a monoclonal antibody directed against the large subunit of RPA, RPA70. In contrast to immunoprecipitations with antibodies to the entire RPA complex (compare Fig. 2 ), unphosphorylated but not hyperphosphorylated RPA32 was co-immunoprecipitated (Fig. 6, lanes 5 and 6) . As these immunoprecipitations were performed under physiological salt conditions, hyperphosphorylated RPA32 appears to be weaker bound to the trimeric RPA complex than unphosphorylated RPA32 and might also dissociate from the complex in vivo.
DISCUSSION
In the present study, we have investigated the fate of RPA during apoptosis. We demonstrated that a subpopulation of RPA32 is rapidly phosphorylated in a reaction which most likely requires the activity of DNA-PK and of a CDK. Phosphorylation results in a hyperphosphorylated form with reduced electrophoretic mobility and appears to affect the interaction of RPA32 with other subunits of the RPA complex.
In Jurkat cells induced to undergo apoptosis, hyperphosphorylation of RPA32 occurs stepwise, with intermediates detectable at early, but not at late stages of apoptosis (Fig. 1) . However, even at late time points when >95% of the cells display apoptotic phenotype, phosphorylation of RPA32 seems to be limited to only ∼20% of RPA32. This limitation was reproducibly found in many independent experiments and could be due to the existence of two subpopulations of RPA in the nucleus. Indeed, recent experiments from this laboratory have shown that RPA is present in a free and a chromatin-bound fraction with 75 and 25%, respectively (30) . It is therefore conceivable that only the chromatin-bound, but not the free subpopulation of RPA is subject to phosphorylation during apoptosis. The limitation of phosphorylation to a defined fraction of RPA32 suggests that phosphorylation may not simply be a by-product of increased kinase activity in apoptotic cells, but rather a controlled and specific event. This conclusion is supported by the experiment of Figure 2A (left) , where we compared the patterns of phosphorylated proteins in total cell extracts from apoptotic and from non-apoptotic cells. Neither a qualitative nor a quantitative difference in phosphorylation can be detected between proteins from apoptotic and control cells, arguing against a strong general kinase activation during apoptosis that would lead to a fortuitous phosphorylation of RPA32 (or other proteins).
Phosphorylation of RPA32 can be partially prevented by inhibitors of DNA-PK and of CDKs, and is almost completely blocked by a combination of both inhibitors. This result suggests that both kinase activities are involved in the phosphorylation of RPA32 during apoptosis, as in the case of phosphorylation of RPA32 in cyclin A-activated G 1 extracts (15) . In these extracts, the hyperphosphorylated form of RPA32 results from the combined actions of CDK2 and DNA-PK. In vitro, RPA32 can be phosphorylated both by CDKs and DNA-PK (15, 18, 21, 23) , but most published evidence seems to indicate that phosphorylation of RPA in vivo is mainly carried out by DNA-PK (22,24 and references therein). However, our data strongly suggest that both a CDK activity and a DNA-PK activity are required for RPA32 phosphorylation in apoptosis.
Interestingly, both kinase activities have been implicated in apotosis before. While DNA-PK is inactivated by proteolytic cleavage of its catalytic subunit during apoptosis (41, 42) , CDK2 is activated by cleavage of its physiological inhibitor p21 (CIP1/WAF1) (43, 44) . In both cases, cleavage is catalysed by the main effector protease in T-cell apoptosis, caspase 3 (CPP32). We have therefore used SAF-A as a control substrate which is known to be cleaved by caspase 3 in vitro and in vivo (34, and unpublished data). Thus, cleavage of SAF-A is a convenient indicator of increased caspase 3 activity in apoptotic cells. Accordingly, phosphorylation of RPA32 begins before activation of caspase 3 ( Fig. 1) , at a time when DNA-PK is still active while CDKs are not yet activated. In addition, phosphorylation of RPA32 is hardly affected by specific inhibition of caspase 3 (Fig. 3) . Since phosphorylation begins when the first degradation of genomic DNA into high molecular weight fragments is initiated, it is most likely that the kinase catalysing the initial phosphorylation of RPA32 is DNA-PK. Presumably, DNA-PK recognises and signals the lesions that occur during the first apoptotic DNA strand scissions. Later in apoptosis, CDKs could continue the phosphorylation of RPA32.
Sucrose gradient analyses reveal three apoptotic changes in RPA. First, when investigated at low salt concentrations, RPA from apoptotic cells sediments heterogeneously with sedimentation coefficients ranging from 5S to >18S (not shown). In contrast, RPA from control cells sediments with a uniform peak at ∼5S, as described by others before (45, 46) . As the same fractions of the gradient from apoptotic cells but not from control cells contain DNA, we conclude that this shift in sedimentation is due to the binding of RPA to DNA fragments that result from DNA degradation during apoptosis. Second, when analysed under conditions of high ionic strength to disrupt DNA binding, a conformational change of the apoptotic RPA complex becomes evident by an increase in sedimentation rate. This may be related to the flexible structure of the RPA complex revealed by visualisation of DNA-bound RPA complexes (47) and by changes in the proteolytic sensitivity of RPA after binding to ssDNA (48) . Our experiments suggest that the conformational change of RPA induced by DNA binding is not reversed when DNA is separated from the complex by high salt. The third and probably most interesting change of RPA in apoptotic cells is that the hyperphosphorylated, but not the less phosphorylated forms of RPA32 dissociate from the heterotrimer at moderately elevated salt concentrations. This finding was surprising to us, as the RPA complex is known to be extraordinarily stable and can tolerate up to 6 M urea (1,3) or 2 M guanidine-HCl (5) without dissociation. It thus appears that hyperphosphorylated RPA32 is much weaker bound to the complex than unphosphorylated RPA32. This finding was supported by the immunoprecipitation of the RPA complex with monoclonal antibodies to RPA70, as the precipitated complex does not contain hyperphosphorylated RPA32 (Fig. 6 ). In contrast, polyclonal antibodies to the entire RPA complex precipitate hyperphosphorylated RPA32 as well as unphosphorylated RPA32 ( Fig. 2A, right) . Further experiments are necessary to show whether the weak binding of hyperphosphorylated RPA32 to the trimeric complex is an effect observable only during apoptosis, or whether it also occurs during DNA synthesis or in response to DNA damage.
As pointed out in the introduction, the physiological role of RPA phosphorylation is not clear, but could be involved in signalling the presence of ssDNA during normal or pathological DNA metabolic events (5) . During apoptosis, hyperphosphorylated RPA32 could be part of a signalling pathway that blocks cell-cycle progression once the apoptotic cell death program is induced. In this scenario, the apoptotic degradation of DNA could activate DNA-PK to initially phosphorylate RPA32. Hyperphosphorylation by the additional activity of CDKs could later possibly cause a release of hyperphosphorylated RPA32 from the trimeric complex. Phosphorylated RPA32, either as a free subunit or as a component of the RPA trimer, may then interact with other proteins to block DNA repair, replication and cell cycle progression.
